Orthotopic bladder cancer xenografts are the gold standard to study molecular cellular manipulations and new therapeutic agents in vivo. Suitable cell lines are inoculated either by intravesical instillation (model of nonmuscle invasive growth) or intramural injection into the bladder wall (model of invasive growth). Both procedures are complex and highly time-consuming. Additionally, the superficial model has its shortcomings due to the lack of cell lines that are tumorigenic following instillation. Intramural injection, on the other hand, is marred by the invasiveness of the procedure and the associated morbidity for the host mouse.
Introduction
Cancer research is dependent on animal models of human cancer using cell lines derived from patient tumors in order to deepen our understanding of tumor biology. For in vivo growth analysis under different treatment strategies murine orthotopic bladder cancer models remain the reference standard 1, 2 . The inoculation of human bladder cancer cells in immunocompromised mice (xenograft model) relies on intravesical instillation ("intravesical model") 3, 4, 5 or direct injection into the bladder wall ("intramural model") 6, 7 . Both techniques can also be performed in rats 8, 9 .
Intravesical instillation induces the formation of tumors on the urothelial surface of the bladder which then are amenable to subsequent intravesical instillation of novel treatment agents. However, the number of cell lines which are reliably tumorigenic when delivered via this method is limited and one of those cell lines, KU7, has recently been demonstrated to be HeLa 4, 10 . Intravesical instillation is also time consuming due to necessary dwell times, and it frequently induces tumor growth in adjacent elements of the urinary tract, including urethra, ureter, and renal pelvis 11 . Furthermore, intravesical instillation often leads to tumor growth on the floor of the bladder where the ureters enter the bladder, and this can cause upper tract obstruction and concomitant renal failure.
Primary invasive bladder cancer xenografts which are suitable for systemic treatments are created by direct injection of tumor cells into the bladder wall 12 . Although numerous cell lines grow adequately in this model, its limitation is the invasiveness of the model related to the need for an abdominal incision 13 . The model is also challenging to learn due to the technical difficulty of injecting cells precisely into the muscle wall of the bladder.
A novel approach to establish orthotopic primary invasive bladder cancer xenografts in mice has been developed in our department in order to address existing shortcomings of the "intramural model". We were able to optimize the percutaneous, ultrasound-guided injection of bladder cancer cells into the anterior bladder wall resulting in this novel technique to successfully replace the established invasive model. Moreover we have potentially enhanced the accuracy and reproducibility of the "intramural model". 
Discussion
Almost all major advances in cancer therapy will require testing in animal models before initiating clinical trials. Animal models of cancer are essential tools that enable researchers to study tumor biology in vivo. Orthotopic xenograft models remain the gold standard 1,2 and continue to offer the most flexibility (in terms of selection of cell lines) and have the most practical utility.
The illustrated procedure is a minimally invasive modification of the orthotopic model previously described by Dinney et al. 12 We established xenograft tumors by ultrasound guided percutaneous injection of three different cell lines with a technical success rate of 100%. During continuous follow-up, 98% of mice demonstrated constant increase in tumor volume.
By performing a minimally-invasive technique we were able to address existing limitations of the intramural model. Besides respecting animal welfare, the reduced invasiveness of this procedure also contributes to reproducibility of in vivo experiments by decreasing the number of surgical complications. It is highly time effective to avoid an abdominal laparotomy and associated need for wound closure. We were able to decrease significantly the procedure time per animal to 3.4 min (±1.6). However, the chief advantage of our novel approach is its accuracy. Highresolution ultrasound allows us to visualize the space created by saline injection under the mucosa of the bladder wall. This first step injection facilitates tumor cell injection in a second step and minimizes the risk of tumor cell spillage. This contrasts to the technique of intramural injection after laparotomy, where it is impossible to visualize needle placement and there is always an element of uncertainty regarding the exact depth of injection. Also, as we are inoculating tumor cells strictly into the anterior bladder wall, tumor growth on the posterior bladder wall is avoided. Subsequently the rate of obstructive complications due to tumor growth in proximity of the ureteral orifices is extremely rare. This accompanying effect allows longer growth and treatment periods.
The main limitation of the ultrasound-guided tumor inoculation is the need for adequate technical equipment. Therefore the performance of this procedure will likely be restricted to centers which are specialized in animal models of human cancer. This should encourage collaborations between research groups outside of these institutions and the groups with expertise in such novel animal modeling.
Although dependent on familiarity with ultrasound imaging and some manual dexterity, this model is easy to learn under competent instruction. The key step in the procedure is the creation of an artificial space submucosally in the bladder wall with saline. Once this space is created without perforation of the mucosal layer, it remains stable for several minutes. The guidance of the second needle into this space in order to inoculate the tumor cells is relatively simple. The main complication during the creation of the submucosal space is perforation of the needle into the bladder lumen. The creation of a submucosal space, however, remains feasible. The needle has to be withdrawn slowly into the bladder wall and the saline injected just when the mucosal layer flips over the tip of the needle. After this maneuver the submucosal space is less stable (saline will escape to the bladder lumen within 30-60 sec) and the injection of the tumor cells has to be performed quickly. Spillage of tumor cells into the bladder lumen can occur in these cases with perforation of the mucosa. Although the loss of tumor cells from the intramural space might lead to a decreased tumor volume during follow-up, we have never observed any intravesical tumor uptake.
Another potential complication is the spillage of tumor cells to the peritoneal cavity through the injection channel. We observed only one intraperitoneal tumor cell dissemination in 50 animals, and this occurred in one of our first attempts. We attribute this to the injection of too large a tumor cell suspension volume. This was supported by the fact that reducing the volume from 50-40 µl resulted in no further intraperitoneal spillage.
This minimally invasive inoculation of murine orthotopic bladder cancer xenograft represents an innovative modification of the existing "intramural model", benefitting both the investigator and the animals equally. The advantages of this model encourage its adaptation to other organs such as kidney, prostate and liver in order to establish orthotopic xenograft tumors in a minimally-invasive fashion.
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